All Stories

  1. Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients

    Article • Pharmacogenomics, September 2018, Future Medicine

    Professor Anthonius de Boer

  2. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study

    Article • Pharmacoepidemiology and Drug Safety, January 2017, Wiley

    Professor Anthonius de Boer

  3. Risk of fracture in patients with Charcot–Marie–Tooth disease

    Article • Muscle & Nerve, November 2014, Wiley

    Professor Anthonius de Boer

  4. Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling

    Article • Drug Discovery Today, September 2014, Elsevier

    Professor Anthonius de Boer

  5. CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

    Article • American Heart Journal, July 2014, Elsevier

    Professor Anthonius de Boer

  6. Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study

    Article • Journal of Clinical Epidemiology, July 2014, Elsevier

    Professor Anthonius de Boer

  7. Pharmacogenetic‐guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon

    Article • British Journal of Clinical Pharmacology, March 2014, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  8. Pharmacogenomics of oral antiplatelet drugs

    Article • Pharmacogenomics, March 2014, Future Medicine

    Professor Anthonius de Boer

  9. Essential Medicines Are More Available than Other Medicines around the Globe

    Article • PLoS ONE, February 2014, PLOS

    Professor Anthonius de Boer

  10. Disease History and Medication Use as Risk Factors for the Clinical Manifestation of Type 1 Diabetes in Children and Young Adults: An Explorative Case Control Study

    Article • PLoS ONE, February 2014, PLOS

    Professor Anthonius de Boer

  11. Propensity score balance measures in pharmacoepidemiology: a simulation study

    Article • Pharmacoepidemiology and Drug Safety, January 2014, Wiley

    Professor Anthonius de Boer

  12. Changes in Mortality Patterns Following Total Hip or Knee Arthroplasty Over the Past Two Decades: A Nationwide Cohort Study

    Article • Arthritis & Rheumatology, January 2014, Wiley

    Professor Anthonius de Boer

  13. CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis

    Article • Current Drug Safety, December 2013, Bentham Science Publishers

    Professor Anthonius de Boer

  14. A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon

    Article • New England Journal of Medicine, December 2013, New England Journal of Medicine (NEJM/MMS)

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  15. Performance of instrumental variable methods in cohort and nested case–control studies: a simulation study

    Article • Pharmacoepidemiology and Drug Safety, December 2013, Wiley

    Professor Anthonius de Boer

  16. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary arte...

    Article • Pharmacogenetics and Genomics, October 2013, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  17. Five-year fracture risk estimation in patients with Parkinson's disease

    Article • Bone, October 2013, Elsevier

    Professor Anthonius de Boer

  18. Risk of Gastrointestinal Bleeding in Patients Undergoing Total Hip or Knee Replacement Compared With Matched Controls: A Nationwide Cohort Study

    Article • The American Journal of Gastroenterology, August 2013, Wolters Kluwer Health

    Professor Anthonius de Boer

  19. Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making

    Article • PharmacoEconomics, July 2013, Springer Science + Business Media

    Professor Anthonius de Boer

  20. Increased Risk of Sudden Cardiac Arrest in Obstructive Pulmonary Disease: A Case-Control Study

    Article • PLoS ONE, June 2013, PLOS

    Professor Anthonius de Boer

  21. Cost–effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation

    Article • Pharmacogenomics, June 2013, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  22. Should non-inferiority drug trials be banned altogether?

    Article • Drug Discovery Today, June 2013, Elsevier

    Professor Anthonius de Boer

  23. Phase IV non-inferiority trials and additional claims of benefit

    Article • BMC Medical Research Methodology, May 2013, Springer Science + Business Media

    Professor Anthonius de Boer

  24. Use of Oral Glucocorticoids and the Risk of Pulmonary Embolism

    Article • CHEST Journal, May 2013, Elsevier

    Professor Anthonius de Boer

  25. Expert-opinion on non-inferiority margin: A case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery

    Article • Thrombosis Research, April 2013, Elsevier

    Professor Anthonius de Boer

  26. Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis

    Article • PLoS Medicine, March 2013, PLOS

    Professor Anthonius de Boer

  27. Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis

    Article • Pharmacogenomics, February 2013, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  28. Electrocardiographic Characteristics of Patients with Chronic Obstructive Pulmonary Disease

    Article • COPD Journal of Chronic Obstructive Pulmonary Disease, January 2013, Taylor & Francis

    Professor Anthonius de Boer

  29. Evaluation of the effect of genetic variations inGATA-4on the phenprocoumon and acenocoumarol maintenance dose

    Article • Pharmacogenomics, December 2012, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  30. The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon

    Article • British Journal of Clinical Pharmacology, November 2012, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  31. Cardiac Arrhythmias in Adult Patients with Asthma

    Article • Journal of Asthma, September 2012, Taylor & Francis

    Professor Anthonius de Boer

  32. Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose

    Article • Drug Metabolism and Drug Interactions, September 2012, De Gruyter

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  33. Timing of Acute Myocardial Infarction in Patients Undergoing Total Hip or Knee Replacement

    Article • Archives of Internal Medicine, September 2012, American Medical Association (AMA)

    Professor Anthonius de Boer

  34. Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

    Article • Pharmacogenomics, September 2012, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  35. Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions

    Article • Value in Health, September 2012, Elsevier

    Professor Anthonius de Boer

  36. Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study

    Article • Pharmacogenomics, August 2012, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  37. Correction: Differential Changes in QTc Duration during In-Hospital Haloperidol Use

    Article • PLoS ONE, July 2012, PLOS

    Professor Anthonius de Boer

  38. Correction: Common Variants in the Type 2 Diabetes KCNQ1 Gene Are Associated with Impairments in Insulin Secretion During Hyperglycaemic Glucose Clamp

    Article • PLoS ONE, June 2012, PLOS

    Professor Anthonius de Boer, Professor Dorret I Boomsma

  39. Cardiovascular Pharmacogenetics

    Article • April 2012, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  40. Future of Pharmacogenetics in Cardiovascular Diseases

    Article • March 2012, IntechOpen

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  41. Common Variants in the Type 2 Diabetes KCNQ1 Gene Are Associated with Impairments in Insulin Secretion During Hyperglycaemic Glucose Clamp

    Article • PLoS ONE, March 2012, PLOS

    Professor Anthonius de Boer, Professor Dorret I Boomsma

  42. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting

    Article • Pharmacogenetics and Genomics, March 2012, Wolters Kluwer Health

    Professor Anthonius de Boer

  43. When to publish measures of disproportionality derived from spontaneous reporting databases?

    Article • British Journal of Clinical Pharmacology, November 2011, Wiley

    Professor Anthonius de Boer

  44. Acid suppressants and hip fracture: Duplicate publication bias?

    Article • Bone, October 2011, Elsevier

    Professor Anthonius de Boer

  45. Balance measures for propensity score methods: a clinical example on beta‐agonist use and the risk of myocardial infarction

    Article • Pharmacoepidemiology and Drug Safety, September 2011, Wiley

    Professor Anthonius de Boer

  46. Differential Changes in QTc Duration during In-Hospital Haloperidol Use

    Article • PLoS ONE, September 2011, PLOS

    Professor Anthonius de Boer

  47. Implementation of pharmacogenetics in clinical practice is challenging

    Article • Pharmacogenomics, September 2011, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  48. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI

    Article • Atherosclerosis, August 2011, Elsevier

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  49. Measuring balance and model selection in propensity score methods

    Article • Pharmacoepidemiology and Drug Safety, July 2011, Wiley

    Professor Anthonius de Boer

  50. Insomnia medication: Do published studies reflect the complete picture of efficacy and safety?

    Article • European Neuropsychopharmacology, July 2011, Elsevier

    Professor Anthonius de Boer

  51. Influence of the use of functional foods enriched with phytosterols/‐stanols on adherence to statin therapy

    Article • Pharmacoepidemiology and Drug Safety, June 2011, Wiley

    Professor Anthonius de Boer

  52. Time‐trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study

    Article • European Journal of Heart Failure, May 2011, Wiley

    Professor Anthonius de Boer

  53. Non‐steroidal anti‐inflammatory drugs and risk of pulmonary embolism

    Article • Pharmacoepidemiology and Drug Safety, April 2011, Wiley

    Professor Anthonius de Boer

  54. CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel

    Article • Pharmacogenomics, February 2011, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  55. Non‐selective vs. selective beta‐blocker treatment and the risk of thrombo‐embolic events in patients with heart failure

    Article • European Journal of Heart Failure, February 2011, Wiley

    Professor Anthonius de Boer

  56. Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients

    Article • Platelets, December 2010, Taylor & Francis

    Professor Anthonius de Boer

  57. Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction

    Article • Pharmacogenetics and Genomics, December 2010, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  58. Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus

    Article • Drugs, December 2010, Springer Science + Business Media

    Professor Anthonius de Boer

  59. Room for Improvement in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs: A Systematic Review

    Article • PLoS ONE, October 2010, PLOS

    Professor Anthonius de Boer

  60. Pharmacogenetic interactions betweenABCB1andSLCO1B1tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction

    Article • Pharmacogenomics, August 2010, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  61. Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin

    Article • Expert Review of Pharmacoeconomics & Outcomes Research, August 2010, Taylor & Francis

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  62. A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives

    Article • Pharmacogenomics, July 2010, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  63. Use of Organic Nitrates and the Risk of Hip Fracture: A Population-Based Case-Control Study

    Article • The Journal of Clinical Endocrinology & Metabolism, April 2010, Endocrine Society

    Professor Anthonius de Boer

  64. NON-SELECTIVE BETA-BLOCKERS DECREASE THROMBOTIC EVENTS IN PATIENTS WITH HEART FAILURE

    Article • Journal of the American College of Cardiology, March 2010, Elsevier

    Professor Anthonius de Boer

  65. TIME TRENDS IN CARDIOVASCULAR DRUG TREATMENT AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE HEART FAILURE

    Article • Journal of the American College of Cardiology, March 2010, Elsevier

    Professor Anthonius de Boer

  66. Methodological and statistical issues in pharmacogenomics

    Article • Journal of Pharmacy and Pharmacology, February 2010, Oxford University Press (OUP)

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  67. Genetic polymorphisms related to the renin–angiotensin–aldosterone system and response to antihypertensive drugs

    Article • Expert Opinion on Drug Metabolism & Toxicology, January 2010, Informa Healthcare

    Professor Anthonius de Boer

  68. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation

    Article • Pharmacogenetics and Genomics, January 2010, Wolters Kluwer Health

    Professor Anthonius de Boer

  69. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design

    Article • Pharmacogenomics, October 2009, Future Medicine

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  70. Systematic Review of Pharmacogenetic Warfarin Dosing

    Article • Journal of General Internal Medicine, August 2009, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  71. Genetic determinants of response to statins

    Article • Expert Review of Cardiovascular Therapy, August 2009, Taylor & Francis

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  72. Clinical impact of adducin polymorphism

    Article • Journal of Hypertension, June 2009, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  73. Reasons for non‐response in observational pharmacogenetic research

    Article • Pharmacoepidemiology and Drug Safety, May 2009, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  74. Pharmacogenomic insights into treatment and management of statin-induced myopathy

    Article • Genome Medicine, January 2009, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  75. Interaction between the Gly460Trp α-adducin gene variant and diuretics on the risk of myocardial infarction

    Article • Journal of Hypertension, January 2009, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  76. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment

    Article • November 2008

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  77. Effect of oral antiplatelet agents on major bleeding in users of coumarins

    Article • Thrombosis and Haemostasis, November 2008, Schattauer GmbH

    Professor Anthonius de Boer

  78. Comparison of knowledge and accessibility to information sources of HIV/AIDS between blind and sighted populations in Nigeria

    Article • AIDS Care, September 2008, Taylor & Francis

    Professor Anthonius de Boer

  79. Pharmacogenomics of coumarin anticoagulants: Are we underestimating the role of CYP2C9?

    Article • Thrombosis and Haemostasis, July 2008, Schattauer GmbH

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  80. Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant

    Article • Pharmacogenetics and Genomics, July 2008, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  81. Comparison of different pain scoring systems in critically ill patients in a general ICU

    Article • Critical Care, February 2008, Springer Science + Business Media

    Professor Anthonius de Boer

  82. Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods

    Article • Pharmacoepidemiology and Drug Safety, October 2007, Wiley

    Professor Anthonius de Boer

  83. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution

    Article • British Journal of Clinical Pharmacology, September 2007, Wiley

    Professor Anthonius de Boer

  84. Pharmacogenetics of Glucose-Lowering Drug Treatment

    Article • Molecular Diagnosis & Therapy, September 2007, Springer Science + Business Media

    Professor Anthonius de Boer

  85. Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study

    Article • Journal of Hypertension, March 2007, Wolters Kluwer Health

    Professor Anthonius de Boer

  86. Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction

    Article • European Journal of Clinical Pharmacology, February 2007, Springer Science + Business Media

    Professor Anthonius de Boer

  87. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or β-blockers

    Article • European Journal of Human Genetics, February 2007, Springer Science + Business Media

    Professor Anthonius de Boer

  88. Economic Evaluations of Cholesterol-Lowering Drugs

    Article • PharmacoEconomics, January 2007, Springer Science + Business Media

    Professor Anthonius de Boer

  89. Discrepancies between medication records of anticoagulation clinics and pharmacy records

    Article • Pharmacoepidemiology and Drug Safety, July 2006, Wiley

    Professor Anthonius de Boer

  90. Apoliprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS)

    Article • Acta Cardiologica, June 2006, Peeters Publishers

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  91. The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure

    Article • European Journal of Human Genetics, May 2006, Springer Science + Business Media

    Professor Anthonius de Boer

  92. Instrumental Variables

    Article • Epidemiology, May 2006, Wolters Kluwer Health

    Professor Anthonius de Boer

  93. Initial non‐compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy

    Article • Pharmacoepidemiology and Drug Safety, April 2006, Wiley

    Professor Anthonius de Boer

  94. Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992–1999)

    Article • British Journal of Clinical Pharmacology, February 2006, Wiley

    Professor Anthonius de Boer

  95. Improving Pharmacotherapy After Myocardial Infarction by Group Academic Detailing Using Feedback Data on a Patient Level

    Article • Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, February 2006, Wiley

    Professor Anthonius de Boer

  96. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation

    Article • Journal of Clinical Epidemiology, January 2006, Elsevier

    Professor Anthonius de Boer

  97. A Comparison of Two Multiple-Characteristic Decision-Making Models for the Comparison of Antihypertensive Drug Classes

    Article • American Journal of Cardiovascular Drugs, January 2006, Springer Science + Business Media

    Professor Anthonius de Boer

  98. Rate and determinants of 10-year persistence with antihypertensive drugs

    Article • Journal of Hypertension, November 2005, Wolters Kluwer Health

    Professor Anthonius de Boer

  99. Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: A retrospective analysis

    Article • Clinical Therapeutics, November 2005, Elsevier

    Professor Anthonius de Boer

  100. Cardiovascular drug use and differences in the incidence of cardiovascular mortality in elderly Serbian men

    Article • April 2005

    Professor Anthonius de Boer

  101. Suboptimal choices and dosing of statins at start of therapy

    Article • British Journal of Clinical Pharmacology, March 2005, Wiley

    Professor Anthonius de Boer

  102. Genetic Polymorphisms and Response to HMG-CoA Reductase Inhibitors

    Article • January 2005, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  103. Discontinuation of rivastigmine in routine clinical practice

    Article • International Journal of Geriatric Psychiatry, January 2005, Wiley

    Professor Anthonius de Boer

  104. Pharmacogenetics in health-care practice

    Article • Pharmacy World & Science, October 2004, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  105. Should rosuvastatin be withdrawn from the market?

    Article • The Lancet, October 2004, Elsevier

    Professor Anthonius de Boer

  106. Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?

    Article • Pharmacy World & Science, October 2004, Springer Science + Business Media

    Professor Anthonius de Boer

  107. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen

    Article • Journal of Hypertension, September 2004, Wolters Kluwer Health

    Professor Anthonius de Boer

  108. Pre-randomization decisions and group stratification in a randomized controlled trial to improve prescribing

    Article • Pharmacy World & Science, August 2004, Springer Science + Business Media

    Professor Anthonius de Boer

  109. Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands

    Article • British Journal of Clinical Pharmacology, June 2004, Wiley

    Professor Anthonius de Boer

  110. Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness

    Article • Journal of Clinical Epidemiology, March 2004, Elsevier

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  111. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting ??-hydroxy-??-methylglutaryl coenzyme A reductase inhibitor therapy in men

    Article • Pharmacogenetics, January 2004, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  112. Failure to Continue Lipid-Lowering Drug Use Following the Withdrawal of Cerivastatin

    Article • Drug Safety, January 2004, Springer Science + Business Media

    Professor Anthonius de Boer

  113. Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy

    Article • Drugs, January 2004, Springer Science + Business Media

    Professor Anthonius de Boer

  114. Drug Therapy for Prevention of Recurrent Myocardial Infarction

    Article • Annals of Pharmacotherapy, October 2003, SAGE Publications

    Professor Anthonius de Boer

  115. Adherence to and dosing of ??-hydroxy-??-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes

    Article • Pharmacogenetics, April 2003, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  116. Oral Antithrombotic Use Among Myocardial Infarction Patients

    Article • Annals of Pharmacotherapy, January 2003, SAGE Publications

    Professor Anthonius de Boer

  117. Pharmacotherapy of Hospitalised HIV-Infected Patients in a General Hospital during 1990, 1997 and 2001

    Article • Clinical Drug Investigation, January 2003, Springer Science + Business Media

    Professor Anthonius de Boer

  118. Myopathy Due to Statin/Fibrate Use in the Netherlands

    Article • Annals of Pharmacotherapy, December 2002, SAGE Publications

    Professor Anthonius de Boer

  119. Adherence to and dosing of statins differs according to apolipoprotein E-genotypes

    Article • British Journal of Clinical Pharmacology, November 2002, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  120. The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype

    Article • Pharmacogenetics, November 2002, Wolters Kluwer Health

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  121. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors

    Article • Atherosclerosis, August 2002, Elsevier

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  122. Authorʼs Reply:

    Article • Annals of Pharmacotherapy, July 2002, SAGE Publications

    Professor Anthonius de Boer

  123. The effectiveness of HMG‐CoA reductase inhibitors in an elderly population is independent of apolipoprotein E‐genotypes

    Article • British Journal of Clinical Pharmacology, May 2002, Wiley

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  124. Lipid-Lowering Drug Use and Cardiovascular Events after Myocardial Infarction

    Article • Annals of Pharmacotherapy, May 2002, SAGE Publications

    Professor Anthonius de Boer

  125. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?

    Article • British Journal of Clinical Pharmacology, April 2002, Wiley

    Professor Anthonius de Boer

  126. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case–control study

    Article • Pharmacogenetics, April 2002, Wolters Kluwer Health

    Professor Anthonius de Boer

  127. Discrepancies between Medical and Pharmacy Records for Patients on Anti-HIV Drugs

    Article • Annals of Pharmacotherapy, March 2002, SAGE Publications

    Professor Anthonius de Boer

  128. Do the research goal and databases match? A checklist for a systematic approach

    Article • Health Policy, December 2001, Elsevier

    Professor Anthonius de Boer

  129. Risk of Extrapyramidal Syndromes with Haloperidol, Risperidone, or Olanzapine

    Article • Annals of Pharmacotherapy, December 2001, SAGE Publications

    Professor Anthonius de Boer

  130. Thoracic and thoracoabdominal aortic aneurysm repair: Use of evoked potential monitoring in 118 patients

    Article • Journal of Vascular Surgery, December 2001, Elsevier

    Professor Anthonius de Boer

  131. Comparison of different methods to estimate prevalence of drug use by using pharmacy records

    Article • Journal of Clinical Epidemiology, November 2001, Elsevier

    Professor Anthonius de Boer

  132. Is Drug Treatment of Hypertension in Clinical Practice as Effective as in Randomized Controlled Trials with Regard to the Reduction of the Incidence of Stroke?

    Article • Epidemiology, May 2001, Wolters Kluwer Health

    Professor Anthonius de Boer

  133. Antihypertensive Drug Therapies and the Risk of Ischemic Stroke

    Article • Archives of Internal Medicine, January 2001, American Medical Association (AMA)

    Professor Anthonius de Boer

  134. Drug-Induced Lipid Changes

    Article • Drug Safety, January 2001, Springer Science + Business Media

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  135. Lipid Abnormalities Induced by Novel Antipsychotic Drugs

    Article • Drug Safety, January 2001, Springer Science + Business Media

    Professor Anthonius de Boer

  136. The interface between pharmacoepidemiology and pharmacogenetics

    Article • European Journal of Pharmacology, December 2000, Elsevier

    Dr Anke H Maitland-van der Zee, Professor Anthonius de Boer

  137. Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure

    Article • Journal of Clinical Epidemiology, November 2000, Elsevier

    Professor Anthonius de Boer

  138. The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards

    Article • British Journal of Clinical Pharmacology, June 2000, Wiley

    Professor Anthonius de Boer

  139. Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects

    Article • Journal of Clinical Epidemiology, June 2000, Elsevier

    Professor Anthonius de Boer

  140. Influence of question structure on the recall of self-reported drug use

    Article • Journal of Clinical Epidemiology, March 2000, Elsevier

    Professor Anthonius de Boer

  141. The relationship between evoked potentials and measurements of S-100 protein in cerebrospinal fluid during and after thoracoabdominal aortic aneurysm surgery

    Article • Journal of Vascular Surgery, August 1999, Elsevier

    Professor Anthonius de Boer

  142. Excess Stroke Among Hypertensive Men and Women Attributable to Undertreatment of Hypertension

    Article • Stroke, July 1999, Wolters Kluwer Health

    Professor Anthonius de Boer

  143. Within patient variability of lower extremity muscle responses to transcranial electrical stimulation with pulse trains in aortic surgery

    Article • Clinical Neurophysiology, June 1999, Elsevier

    Professor Anthonius de Boer

  144. Within-Patient Variability of Myogenic Motor-Evoked Potentials to Multipulse Transcranial Electrical Stimulation During Two Levels of Partial Neuromuscular Blockade in Aortic Surgery

    Article • Anesthesia & Analgesia, January 1999, Wolters Kluwer Health

    Professor Anthonius de Boer

  145. Within-Patient Variability of Myogenic Motor-Evoked Potentials to Multipulse Transcranial Electrical Stimulation During Two Levels of Partial Neuromuscular Blockade in Aortic Surgery

    Article • Anesthesia & Analgesia, January 1999, Wolters Kluwer Health

    Professor Anthonius de Boer

  146. Sex differences in antihypertensive drug use

    Article • Journal of Hypertension, October 1998, Wolters Kluwer Health

    Professor Anthonius de Boer

  147. Undertreatment of hypertension in a population-based study in The Netherlands

    Article • Journal of Hypertension, September 1998, Wolters Kluwer Health

    Professor Anthonius de Boer

  148. Is placebo analgesia mediated by endogenous opioids? A systematic review

    Article • Pain, June 1998, Wolters Kluwer Health

    Professor Anthonius de Boer, Gerben ter Riet

  149. Assessment of control of hypertension in the population

    Article • Journal of Hypertension, March 1998, Wolters Kluwer Health

    Professor Anthonius de Boer

  150. Sex-based differences in the pharmacological treatment of hypertension

    Article • Journal of Hypertension, December 1997, Wolters Kluwer Health

    Professor Anthonius de Boer

  151. Physician-Assisted Death and Pharmacy Practice in the Netherlands

    Article • New England Journal of Medicine, October 1997, New England Journal of Medicine (NEJM/MMS)

    Professor Anthonius de Boer

  152. Reply of the authors

    Article • Fertility and Sterility, June 1997, Elsevier

    Professor Anthonius de Boer

  153. Sex differences in the pharmacological treatment of hypertension

    Article • Journal of Hypertension, June 1997, Wolters Kluwer Health

    Professor Anthonius de Boer

  154. Validation of pharmacy records in drug exposure assessment

    Article • Journal of Clinical Epidemiology, May 1997, Elsevier

    Professor Anthonius de Boer

  155. Current use of thiazide diuretics and prevention of femur fractures

    Article • Journal of Clinical Epidemiology, January 1996, Elsevier

    Professor Anthonius de Boer

  156. Drug Interactions With Thrombolytic Agents

    Article • Clinical Pharmacokinetics, April 1995, Springer Science + Business Media

    Professor Anthonius de Boer

  157. Influence of Chlorthalidone on the Pharmacokinetics and Pharmacodynamics of Org 10172 (Lomoparan®), A Low Molecular Weight Heparinoid, in Healthy Volunteers

    Article • The Journal of Clinical Pharmacology, July 1991, Wiley

    Professor Anthonius de Boer